Bill Langbein

/Bill Langbein

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

By | 2019-03-25T11:45:49-04:00 March 25th, 2019|Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology|

One of the strongest performing biopharmaceutical stocks this year is [...]

ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies

By | 2019-01-22T10:10:21-04:00 January 22nd, 2019|Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|

SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]

Verona (VRNA) Talks Up The Long View Following Phase II Setback

By | 2019-03-07T14:59:36-04:00 January 16th, 2019|Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]

Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2

By | 2019-01-22T10:10:46-04:00 January 2nd, 2019|Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|

SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]

ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible

By | 2018-12-28T10:31:02-04:00 December 28th, 2018|Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|

Shares of ADMA Biologics [NASDAQ:ADMA]  fell more than 45% on [...]

SSL